Yajing Chen Sells 5,199 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 5,199 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total transaction of $106,007.61. Following the sale, the chief financial officer owned 32,558 shares of the company’s stock, valued at $663,857.62. This represents a 13.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Yajing Chen also recently made the following trade(s):

• On Friday, March 13th, Yajing Chen sold 1,703 shares of Zai Lab stock. The shares were sold at an average price of $18.63, for a total transaction of $31,726.89.

Zai Lab Price Performance

Shares of Zai Lab stock opened at $20.41 on Friday. The firm has a market cap of $2.30 billion, a PE ratio of -12.68 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $44.34. The company’s fifty day simple moving average is $18.67 and its two-hundred day simple moving average is $21.75.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) EPS for the quarter. The firm had revenue of $127.60 million for the quarter. Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%. As a group, sell-side analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZLAB has been the subject of several research analyst reports. Jefferies Financial Group upgraded Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. Zacks Research cut Zai Lab from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. UBS Group began coverage on Zai Lab in a report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Cantor Fitzgerald dropped their price target on Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.00.

Institutional Trading of Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC raised its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.